However, in our HFD-fed mice myostatin expression in muscle was not higher (Fig. 3h) and therefore, the effects of neither the anti-myostatin PMO, nor the myostatin propeptide, can be ascribed to the counteraction of an obesity-associated increase in myostatin expression. The gene discussed is MSTN; the disease is obesity due to melanocortin 4 receptor deficiency.